Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by PoorOpinionon Jan 14, 2019 1:25pm

138 Views

Post# 29228696

RE:RE:Endo Facing Multibillion Opioid lawsuits

Just out of curiosity, are the guys running Endo now the same guys running Endo when they bought Paladin?

TheRock077 wrote: Nothing is certain other than Endo is about to go under.

Given his past offer for Paladin in 2016, one might assume with some confidence that Goodie is still interested, particulary as the price of Paladin must have come down quite a bit since 2016.

The recent communications blackout might be related to the imminience of such a mega move.

If it does, what a magnificant achievement for Goodman to have sold his cake very expensively and then to re-acquire it at just 25 % of the sale price.

It is those types of outstanding deals that excites Goodman.

He does , afterall, get his kicks from super achievements.